Skip to content
2000
Volume 32, Issue 18
  • ISSN: 0929-8673
  • E-ISSN: 1875-533X

Abstract

Background

Metabolic syndrome is a multifactorial disorder and genetics, lifestyle, and aging play important roles in its prevalence. has several pharmacological benefits, including anti-inflammatory, antitumor, anti-diabetic, antioxidant, and hypolipidemic effects. This meta-analysis of randomized controlled trials assesses the effect of consumption on lipid profile and glycemic indices in patients with metabolic syndrome.

Methods

We systematically researched Cochrane Library, PubMed, Scopus, and Web of Science databases. The literature research identified 171 studies with duplication. Of those, 73 articles were screened for titles and abstracts, and 7 studies were finally selected for the meta-analysis. Because of the high degree of heterogeneity, we performed subgroup analyses based on the dose of (<=500 mg/day or >500 mg/day).

Results

The results revealed that intake significantly decreased total cholesterol (SMD: −0.71; 95% CI, -1.44 to -0.38; = 0.00), LDL-C (SMD: −1.06; 95% CI, -1.45 to -0.66; = 0.00) and HDL-C (SMD: −0.31; 95% CI, 0.09 to 0.53; = 0.01) concentrations. In addition, significantly decreased FBS (SMD: −0.8; 95% CI, -1.21 to -0.39; = 0.00) and HbA1c (SMD: −0.37; 95% CI, -0.66 to -0.09; = 0.01) concentrations. No publication bias was observed, and sensitivity analysis showed stable results.

Conclusion

The current systematic review and meta-analysis indicates that could improve lipid profile and glycemic index in patients with metabolic syndrome.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cmc/10.2174/0109298673249741231129100733
2024-01-23
2025-10-26

  • From This Site

    /content/journals/cmc/10.2174/0109298673249741231129100733
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. WilbornC. BeckhamJ. CampbellB. HarveyT. GalbreathM. La BountyP. NassarE. WismannJ. KreiderR. Obesity: Prevalence, theories, medical consequences, management, and research directions.J. Int. Soc. Sports Nutr.20052243110.1186/1550‑2783‑2‑2‑418500955
     [Google Scholar]
  2. FahedG. AounL. Bou ZerdanM. AllamS. Bou ZerdanM. BouferraaY. AssiH.I. Metabolic syndrome: Updates on pathophysiology and management in 2021.Int. J. Mol. Sci.202223278610.3390/ijms2302078635054972
     [Google Scholar]
  3. NoubiapJ.J. NansseuJ.R. Lontchi-YimagouE. NkeckJ.R. NyagaU.F. NgouoA.T. TounougaD.N. TianyiF.L. FokaA.J. NdoadoumgueA.L. BignaJ.J. Geographic distribution of metabolic syndrome and its components in the general adult population: A meta-analysis of global data from 28 million individuals.Diabetes Res. Clin. Pract.202218810992410.1016/j.diabres.2022.10992435584716
     [Google Scholar]
  4. EspósitoR.C. de MedeirosP.J. de Souza SilvaF. OliveiraA.G. Soares AragãoC.F. Oliveira RochaH.A. MoreiraS.A. de Farias SalesV.S. Prevalence of the metabolic syndrome according to different criteria in the male population during the Blue November Campaign in Natal, RN, Northeastern Brazil.Diabetes Metab. Syndr. Obes.20181140140810.2147/DMSO.S16843030122967
     [Google Scholar]
  5. GrundyS.M. Metabolic syndrome pandemic.Arterioscler. Thromb. Vasc. Biol.200828462963610.1161/ATVBAHA.107.15109218174459
     [Google Scholar]
  6. NoubiapJ.J. NansseuJ.R. Lontchi-YimagouE. NkeckJ.R. NyagaU.F. NgouoA.T. TounougaD.N. TianyiF.L. FokaA.J. NdoadoumgueA.L. BignaJ.J. Global, regional, and country estimates of metabolic syndrome burden in children and adolescents in 2020: A systematic review and modelling analysis.Lancet Child Adolesc. Health20226315817010.1016/S2352‑4642(21)00374‑635051409
     [Google Scholar]
  7. SrivastavaR. SrivastavaM. VermaP. GautamA. Metabolic syndrome and periodontal disease: An overview for physicians.J. Family Med. Prim. Care20198113492349510.4103/jfmpc.jfmpc_866_1931803642
     [Google Scholar]
  8. AmihăeseiI.C. ChelaruL. Metabolic syndrome a widespread threatening condition; risk factors, diagnostic criteria, therapeutic options, prevention and controversies: An overview.Rev. Med. Chir. Soc. Med. Nat. Iasi2014118489690025581945
     [Google Scholar]
  9. Dobrowolski P.; Prejbisz A.; Kuryłowicz A.; Baska A.; Burchardt P.; Chlebus K.; Dzida G.; Jankowski P.; Jaroszewicz J.; Jaworski P.; Kamiński K.; Kapłon-Cieślicka A.; Klocek M.; Kukla M.; Mamcarz A.; Mastalerz-Migas A.; Narkiewicz K.; Ostrowska L.; Śliż D.; Tarnowski W.; Wolf J.; Wyleżoł M.; Zdrojewski T.; Banach M.; Januszewicz A.; Bogdański P.; Metabolic syndrome - A new definition and management guidelines: A joint position paper by the polish society of hypertension, polish society for the treatment of obesity, polish lipid association, polish association for study of liver, polish society of family medicine, polish society of lifestyle medicine, division of prevention and epidemiology polish cardiac society, "club 30" polish cardiac society, and division of metabolic and bariatric surgery society of polish surgeons. Arch. Med. Sci. 2022 Aug 30; 18(5):1133-1156.10.5114/aoms/15292136160355PMC9479724
  10. LannD. GallagherE. LeroithD. Insulin resistance and the metabolic syndrome.Minerva Med.200899325326218497723
     [Google Scholar]
  11. Silveira RossiJ.L. BarbalhoS.M. Reverete de AraujoR. BecharaM.D. SloanK.P. SloanL.A. Metabolic syndrome and cardiovascular diseases: Going beyond traditional risk factors.Diabetes Metab. Res. Rev.2022383e350210.1002/dmrr.350234614543
     [Google Scholar]
  12. Godoy-MatosA.F. Silva JúniorW.S. ValerioC.M. NAFLD as a continuum: From obesity to metabolic syndrome and diabetes.Diabetol. Metab. Syndr.20201216010.1186/s13098‑020‑00570‑y32684985
     [Google Scholar]
  13. De FlinesJ. ScheenA.J. Management of metabolic syndrome and associated cardiovascular risk factors.Acta Gastroenterol. Belg.201073226126620690566
     [Google Scholar]
  14. HosseiniH. GhavidelF. PanahiG. MajeedM. SahebkarA. A systematic review and meta-analysis of randomized controlled trials investigating the effect of the curcumin and piperine combination on lipid profile in patients with metabolic syndrome and related disorders.Phytother. Res.20233731212122410.1002/ptr.773036649934
     [Google Scholar]
  15. NsiahK. ShangV.O. BoatengK.A. MensahF.O. Prevalence of metabolic syndrome in type 2 diabetes mellitus patients.Int. J. Appl. Basic Med. Res.20155213313810.4103/2229‑516X.15717026097823
     [Google Scholar]
  16. CornierM.A. DabeleaD. HernandezT.L. LindstromR.C. SteigA.J. StobN.R. Van PeltR.E. WangH. EckelR.H. The metabolic syndrome.Endocr. Rev.200829777782210.1210/er.2008‑002418971485
     [Google Scholar]
  17. Cicero, A. F. G.; Sahebkar, A.; Fogacci, F.; Bove, M.; Giovannini, M.; & Borghi, C.; Effects of phytosomal curcumin on anthropometric parameters, insulin resistance, cortisolemia and non-alcoholic fatty liver disease indices: A double-blind, placebo-controlled clinical trial. Eur. J. Nutr., 2020 59(2), 477–483.10.1007/s00394‑019‑01916‑7
  18. ŠimićI. ReinerZ. Adverse effects of statins - myths and reality.Curr. Pharm. Des.20152191220122610.2174/138161282066614101313444725312733
     [Google Scholar]
  19. Bytyçi, I.; Penson, P. E.; Mikhailidis, D. P.; Wong, N. D.; Hernandez, A. V.; Sahebkar, A.; Thompson, P. D.; Mazidi, M.; Rysz, J.; Pella, D.; Reiner, Ž.; Toth P. P.; & Banach, M.; Prevalence of statin intolerance: A meta-analysis. Eur. Heart J., 2022 43(34), 3213–3223M10.1093/eurheartj/ehac015
  20. PattiA.M. Al-RasadiK. GiglioR.V. NikolicD. ManninaC. CastellinoG. ChianettaR. BanachM. CiceroA.F.G. LippiG. MontaltoG. RizzoM. TothP.P. Natural approaches in metabolic syndrome management.Arch. Med. Sci.201814242244110.5114/aoms.2017.6871729593818
     [Google Scholar]
  21. SamS. Importance and effectiveness of herbal medicines.J. Pharmacogn. Phytochem.201982354357
     [Google Scholar]
  22. KhanM.S.A. AhmadI. Herbal medicine: current trends and future prospects. New look to phytomedicine.Elsevier2019313
     [Google Scholar]
  23. AhmadA. HusainA. MujeebM. KhanS.A. NajmiA.K. SiddiqueN.A. DamanhouriZ.A. AnwarF. A review on therapeutic potential of Nigella sativa: A miracle herb.Asian Pac. J. Trop. Biomed.20133533735210.1016/S2221‑1691(13)60075‑123646296
     [Google Scholar]
  24. HannanM.A. RahmanM.A. SohagA.A.M. UddinM.J. DashR. SikderM.H. RahmanM.S. TimalsinaB. MunniY.A. SarkerP.P. AlamM. MohibbullahM. HaqueM.N. JahanI. HossainM.T. AfrinT. RahmanM.M. Tahjib-Ul-ArifM. MitraS. OktavianiD.F. KhanM.K. ChoiH.J. MoonI.S. KimB. Black cumin (Nigella sativa L.): A comprehensive review on phytochemistry, health benefits, molecular pharmacology, and safety.Nutrients2021136178410.3390/nu1306178434073784
     [Google Scholar]
  25. KootiW. Hasanzadeh-NoohiZ. Sharafi-AhvaziN. Asadi-SamaniM. Ashtary-LarkyD. Phytochemistry, pharmacology, and therapeutic uses of black seed (Nigella sativa).Chin. J. Nat. Med.2016141073274510.1016/S1875‑5364(16)30088‑728236403
     [Google Scholar]
  26. ForouzanfarF. BazzazB.S. HosseinzadehH. Black cumin (Nigella sativa) and its constituent (thymoquinone): A review on antimicrobial effects.Iran. J. Basic Med. Sci.2014171292993825859296
     [Google Scholar]
  27. ZaouiA. CherrahY. MahassiniN. AlaouiK. AmarouchH. HassarM. Acute and chronic toxicity of Nigella sativa fixed oil.Phytomedicine200291697410.1078/0944‑7113‑0008411924767
     [Google Scholar]
  28. AliB.H. BlundenG. Pharmacological and toxicological properties of Nigella sativa.Phytother. Res.200317429930510.1002/ptr.130912722128
     [Google Scholar]
  29. DajaniE.Z. ShahwanT.G. DajaniN.E. Overview of the preclinical pharmacological properties of Nigella sativa (black seeds): A complementary drug with historical and clinical significance.J. Physiol. Pharmacol.201667680181728195061
     [Google Scholar]
  30. AhmadM.F. AhmadF.A. AshrafS.A. SaadH.H. WahabS. KhanM.I. AliM. MohanS. HakeemK.R. AtharM.T. An updated knowledge of Black seed (Nigella sativa Linn.): Review of phytochemical constituents and pharmacological properties.J. Herb. Med.20212510040410.1016/j.hermed.2020.10040432983848
     [Google Scholar]
  31. SamarghandianS. FarkhondehT. SaminiF. A review on possible therapeutic effect of Nigella sativa and thymoquinone in neurodegenerative diseases.CNS Neurol. Disord. Drug Targets201817641242010.2174/187152731766618070210145529962349
     [Google Scholar]
  32. KhaderM. EcklP.M. Thymoquinone: An emerging natural drug with a wide range of medical applications.Iran. J. Basic Med. Sci.2014171295095725859298
     [Google Scholar]
  33. RazaviB.M. HosseinzadehH. A review of the effects of Nigella sativa L. and its constituent, thymoquinone, in metabolic syndrome.J. Endocrinol. Invest.201437111031104010.1007/s40618‑014‑0150‑125125023
     [Google Scholar]
  34. MohtashamiA. MahakiB. AzadbakhtL. EntezariM.H. Effects of bread with Nigella Sativa on lipid profiles, apolipoproteins and inflammatory factor in metabolic syndrome patients.Clin. Nutr. Res.201652899510.7762/cnr.2016.5.2.8927152298
     [Google Scholar]
  35. IbrahimR.M. HamdanN.S. IsmailM. SainiS.M. Abd RashidS.N. Abd LatiffL. MahmudR. Protective effects of Nigella sativa on metabolic syndrome in menopausal women.Adv. Pharm. Bull.201441293324409406
     [Google Scholar]
  36. FadisheiM. GhasemzadehR.M. ImenshahidiM. MohajeriA. RazaviB.M. HosseinzadehH. Effects of Nigella sativa oil and thymoquinone against bisphenol A-induced metabolic disorder in rats.Phytother. Res.20213542005202410.1002/ptr.694433315269
     [Google Scholar]
  37. HaasM.J. NaemE. AlmdallalehS. MooradianA.D. The effect of black seed (Nigella sativa) extract on lipid metabolism in HepG2 cells.Biochim. Biophys. Acta Mol. Cell Biol. Lipids20221867815915510.1016/j.bbalip.2022.15915535483558
     [Google Scholar]
  38. HeshmatiJ. NamaziN. Effects of black seed (Nigella sativa) on metabolic parameters in diabetes mellitus: A systematic review.Complement. Ther. Med.201523227528210.1016/j.ctim.2015.01.01325847566
     [Google Scholar]
  39. MoherD. LiberatiA. TetzlaffJ. AltmanD.G. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement.Ann. Intern. Med.20091514264269, W6410.7326/0003‑4819‑151‑4‑200908180‑0013519622511
     [Google Scholar]
  40. CumpstonM LiT PageMJ ChandlerJ WelchVA HigginsJP Updated guidance for trusted systematic reviews: A new edition of the Cochrane Handbook for Systematic Reviews of Interventions.Cochrane Database Syst Rev.20191010.10021465185810.1002/14651858.ED000142
     [Google Scholar]
  41. BorensteinM. HedgesL. HigginsJ. RothsteinH. Comprehensive meta-analysis version 3.Englewood, NJBiostat2013
     [Google Scholar]
  42. HozoS.P. DjulbegovicB. HozoI. Estimating the mean and variance from the median, range, and the size of a sample.BMC Med. Res. Methodol.2005511310.1186/1471‑2288‑5‑1315840177
     [Google Scholar]
  43. HigginsJ.P.T. ThompsonS.G. DeeksJ.J. AltmanD.G. Measuring inconsistency in meta-analyses.BMJ2003327741455756010.1136/bmj.327.7414.55712958120
     [Google Scholar]
  44. DerSimonianR. LairdN. Meta-analysis in clinical trials.Control. Clin. Trials19867317718810.1016/0197‑2456(86)90046‑23802833
     [Google Scholar]
  45. EggerM. SmithG.D. SchneiderM. MinderC. Bias in meta-analysis detected by a simple, graphical test.BMJ1997315710962963410.1136/bmj.315.7109.6299310563
     [Google Scholar]
  46. BeggC.B. BerlinJ.A. Publication bias and dissemination of clinical research.J. Natl. Cancer Inst.198981210711510.1093/jnci/81.2.1072642556
     [Google Scholar]
  47. ShiraziM. KhodakaramiF. FeizabadE. GhaemiM. The effects of Nigella sativa on anthropometric and biochemical indices in postmenopausal women with metabolic syndrome.Endocrine2020691495210.1007/s12020‑020‑02265‑w32236818
     [Google Scholar]
  48. ShahA.S. KhanG.M. BadshahA. ShahS.U. ShahK.U. MirzaS.A. Nigella sativa provides protection against metabolic syndrome.Afr. J. Biotechnol.201211481091910925
     [Google Scholar]
  49. RachmanP. DarmawanE. The efficacy of black cumin seed (Nigella sativa) oil and hypoglycemic drug combination to reduce HbA1c level in patients with metabolic syndrome risk.IOP Conference Series: Materials Science and EngineeringIOP Publishing201710.1088/1757‑899X/259/1/012018
     [Google Scholar]
  50. NajmiA. NasiruddinM. KhanR. HaqueS.F. Therapeutic effect of Nigella sativa in patients of poor glycemic control.Asian J. Pharm. Clin. Res.201253224228
     [Google Scholar]
  51. AminF. IslamN. AnilaN. GilaniA.H. Clinical efficacy of the co-administration of Turmeric and Black seeds (Kalongi) in metabolic syndrome – A double blind randomized controlled trial – TAK-MetS trial.Complement. Ther. Med.201523216517410.1016/j.ctim.2015.01.00825847554
     [Google Scholar]
  52. MohtashamiA. Effects of bread with Nigella sativa on blood glucose, blood pressure and anthropometric indices in patients with metabolic syndrome.Clin. Nutr. Res.20198213814710.7762/cnr.2019.8.2.13831089467
     [Google Scholar]
  53. CustA.E. KaaksR. FriedenreichC. BonnetF. LavilleM. TjønnelandA. OlsenA. OvervadK. JakobsenM.U. ChajèsV. Clavel-ChapelonF. Boutron-RuaultM.C. LinseisenJ. LukanovaA. BoeingH. PischonT. TrichopoulouA. ChristinaB. TrichopoulosD. PalliD. BerrinoF. PanicoS. TuminoR. SacerdoteC. GramI.T. LundE. QuirósJ.R. TravierN. Martínez-GarcíaC. LarrañagaN. ChirlaqueM.D. ArdanazE. BerglundG. LundinE. Bueno-de-MesquitaH.B. van DuijnhovenF.J.B. PeetersP.H.M. BinghamS. KhawK.T. AllenN. KeyT. FerrariP. RinaldiS. SlimaniN. RiboliE. Metabolic syndrome, plasma lipid, lipoprotein and glucose levels, and endometrial cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC).Endocr. Relat. Cancer200714375576710.1677/ERC‑07‑013217914105
     [Google Scholar]
  54. CaoC. SuM. Effects of berberine on glucose-lipid metabolism, inflammatory factors and insulin resistance in patients with metabolic syndrome.Exp. Ther. Med.20191743009301410.3892/etm.2019.729530936971
     [Google Scholar]
  55. PalS.K. ShuklaY. Herbal medicine: Current status and the future.Asian Pac. J. Cancer Prev.20034428128814728584
     [Google Scholar]
  56. NewmanD.J. CraggG.M. Natural products as sources of new drugs over the nearly four decades from 01/1981 to 09/2019.J. Nat. Prod.202083377080310.1021/acs.jnatprod.9b0128532162523
     [Google Scholar]
  57. KarimiA. MajlesiM. Rafieian-KopaeiM. Herbal versus synthetic drugs; beliefs and facts.J. Nephropharmacol.201541273028197471
     [Google Scholar]
  58. SharmaP LongvahT. Nigella (Nigella sativa) seed.Oilseeds: Health Attributes and Food ApplicationsSpringer2021331350
     [Google Scholar]
  59. YimerE.M. TuemK.B. KarimA. Ur-RehmanN. AnwarF. Nigella sativa L. (Black Cumin): A promising natural remedy for wide range of illnesses.Evid. Based Complement. Alternat. Med.2019201911610.1155/2019/152863531214267
     [Google Scholar]
  60. RazmpooshE. SafiS. MazaheriM. Salehi-AbargoueiA. AbdollahiN. NazariM. FallahzadehH. NadjarzadehA. Effects of oral Nigella sativa oil on the expression levels and serum concentrations of adiponectin, PPAR-γ, and TNF-α in overweight and obese women: A study protocol for a crossover-designed, double-blind, placebo-controlled randomized clinical trial.Trials201920151210.1186/s13063‑019‑3568‑031420057
     [Google Scholar]
  61. AhmadS. BegZ.H. Elucidation of mechanisms of actions of thymoquinone-enriched methanolic and volatile oil extracts from Nigella sativa against cardiovascular risk parameters in experimental hyperlipidemia.Lipids Health Dis.20131218610.1186/1476‑511X‑12‑8623758650
     [Google Scholar]
  62. BhattiI.U. RehmanF.U. KhanM.A. MarwatS.K. Effect of prophetic medicine Kalonji (Nigella sativa L.) on lipid profile of human beings: An in vivo approach.World Appl. Sci. J.20096810531057
     [Google Scholar]
  63. AlimohammadiS. HobbenaghiR. JavanbakhtJ. KheradmandD. MortezaeeR. TavakoliM. KhadivarF. AkbariH. RETRACTED ARTICLE: Protective and antidiabetic effects of extract from Nigella sativa on blood glucose concentrations against streptozotocin (STZ)-induced diabetic in rats: an experimental study with histopathological evaluation.Diagn. Pathol.20138113710.1186/1746‑1596‑8‑13723947821
     [Google Scholar]
  64. NajmiA. NasiruddinM. KhanR. HaqueS. Effect of Nigella sativa oil on various clinical and biochemical parameters of insulin resistance syndrome.Int. J. Diabetes Dev. Ctries.2008281111410.4103/0973‑3930.4198019902033
     [Google Scholar]
  65. BamosaA.O. KaatabiH. LebdaaF.M. ElqA.M. Al-SultanbA. Effect of Nigella sativa seeds on the glycemic control of patients with type 2 diabetes mellitus.Indian J. Physiol. Pharmacol.201054434435421675032
     [Google Scholar]
  66. KaatabiH. BamosaA.O. BadarA. Al-ElqA. Abou-HozaifaB. LebdaF. Al-KhadraA. Al-AlmaieS. Nigella sativa improves glycemic control and ameliorates oxidative stress in patients with type 2 diabetes mellitus: Placebo controlled participant blinded clinical trial.PLoS One2015102e011348610.1371/journal.pone.011348625706772
     [Google Scholar]
  67. HosseiniM. MirkarimiS. AminiM. MohtashamiR. KianbakhtS. Fallah HuseiniH. Effects of Nigella sativa l. seed oil in type II diabetic patients: A randomized, double-blind, placebo - controlled clinical trial.Faslnamah-i Giyahan-i Daruyi201312479399
     [Google Scholar]
/content/journals/cmc/10.2174/0109298673249741231129100733
Loading
Effect of Nigella sativa Consumption on Lipid Profile and Glycemic Index in Patients with Metabolic Syndrome: A Systematic Review and Meta-analysis of Randomized Controlled Trials
Curr. Med. Chem. 32, 3638 (2025); https://doi.org/10.2174/0109298673249741231129100733
/content/journals/cmc/10.2174/0109298673249741231129100733
/content/journals/cmc/10.2174/0109298673249741231129100733
Loading

Data & Media loading...

Supplements

file format download Download

  • Article Type:     Review Article
Keyword(s): antioxidant; dyslipidemia; hyperglycemia; meta-analysis; Nigella sativa; randomized controlled trial

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test